Traditional healthcare commercial intelligence relies heavily on billing codes from medical and pharmacy claims data to understand market trends and forecasting. While these legacy sources record what clinical events occurred, they fail to explain the decision-making that went into treatment selection. This leaves brand teams without visibility into the clinical rationales, patient and provider preferences, and other operational factors that drive real-world market share across the product lifecycle.
This whitepaper details how leveraging OMNY Health real-world data gives commercial teams direct visibility into these additional considerations to deliver true launch intelligence. Using a real-world case study in Alzheimer’s disease focused on disease-modifying anti-amyloid therapies, the paper illustrates how converting information from clinical narratives into actionable metrics powers brand strategy across four core pillars:
- Competitive Positioning: Uncovers real-world brand trade-offs, physician preference drivers, and logistical factors such as dosing schedules and administration requirements that influence treatment selection.
- Diagnostic & Lab Alignment: Reveals how specific biomarker metrics and complex lab values actively guide drug choice rather than serving as simple diagnostic checks.
- Unmet Need & Deferral Analysis: Pinpoints why eligible patients go untreated, from specific medical risks and safety fears to administrative hurdles
- Network & Influencer Mapping: Maps cross-specialty referral ecosystems to highlight key gatekeeper specialists halting treatment access.
This guide serves as an end-to-end framework for commercial leadership to convert unstructured clinical narratives into strategic insights that enhance brand performance. Additionally, it defines areas where life science organizations can leverage OMNY Health to strengthen their commercial strategy and optimize drug launches across any therapeutic area.